Biopharmaceuticals
Patent expirations are beckoning generic drug companies, but numerous hurdles remain to a profitable business
Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Copyright © 2025 American Chemical Society
June 6, 2005 Cover
Volume 83, Issue 23
Patent expirations are beckoning generic drug companies, but numerous hurdles remain to a profitable business
Credit:
Pharmaceuticals
Design of an Antismoking Pill
The makers of varenicline got their inspiration from two natural products
Single-molecule Conductivity
Charge state of surface ion regulates current flow through nearby molecule
-
The Name Game
Chemical producers seek to define themselves in a blitz of corporate branding
-
The Nuclear Hot Potato
As radioactive waste mounts and Yucca Mountain stalls, pressure grows for an interim storage site
-
ADVERTISEMENT
New Products
New and Notable in the Chemical Industry
